A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation

American Journal of Gastroenterology

Volumn 110, Issue 5, 2015, Pages 741-748

  Yiannakou, Yan ^a   Piessevaux, Hubert ^b   Bouchoucha, Michel ^c   Schiefke, Ingolf ^d   Filip, Rafal ^e   Gabalec, Libor ^f   Dina, Ion ^g   Stephenson, David ^h   Kerstens, René ⁱ   Etherson, Kevin ^a   Levine, Amy ^j  

^a Department of Occupational Health and Wellbeing   (United Kingdom)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Klinikum St Georg   (Germany)

^e INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^f Orlickoústecká Nemocnice A s   (Czech Republic)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h Shire Pharmaceuticals   (United Kingdom)

ⁱ Movetis NV   (Belgium)

^j SHIRE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BISACODYL; PLACEBO; PRUCALOPRIDE; BENZOFURAN DERIVATIVE; SEROTONIN 4 AGONIST;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CHRONIC CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; DEFECATION HABIT; DIARRHEA; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; INFESTATION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; PARALLEL DESIGN; PATIENT ASSESSMENT OF CONSTIPATION QUALITY OF LIFE; PATIENT ASSESSMENT OF CONSTIPATION SYMPTOM; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOMETRY; QT PROLONGATION; QUALITY OF LIFE ASSESSMENT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS; TREATMENT DURATION; CHEMICALLY INDUCED; CHRONIC DISEASE; CLINICAL TRIAL; DEFECATION; HEADACHE; MEDICAL RECORD; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

ABDOMINAL PAIN; ADULT; AGED; BENZOFURANS; CHRONIC DISEASE; DEFECATION; DIARRHEA; DOUBLE-BLIND METHOD; HEADACHE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; NAUSEA; QUALITY OF LIFE; SEROTONIN 5-HT4 RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84928923452     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.115     Document Type: Article

References (24)

1. Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007 ; 25 : 599-608.
2. Herz MJ, Kahan E, Zalevski S et al. Constipation: a different entity for patients and doctors. Fam Pract 1996 ; 13 : 156-9.
3. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006 ; 130 : 1480-91.
4. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011 ; 106 : 1582-91.
5. Wald A, Scarpignato C, Mueller-Lissner S et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther 2008 ; 28 : 917-30.
6. Belsey J, Greenfield S, Candy D et al. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther 2010 ; 31 : 938-49.
7. Irvine EJ, Ferrazzi S, Pare P et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002 ; 97 : 1986-93.
8. Muller-Lissner S, Tack J, Feng Y et al. Levels of satisfaction with current chronic constipation treatment options in Europe-an internet survey. Aliment Pharmacol Ther 2013 ; 37 : 137-45.
9. Tack J, van Outryve M, Beyens G et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 2009 ; 58 : 357-65.
10. Camilleri M, Kerstens R, Rykx A et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008 ; 358 : 2344-54.
11. Quigley EM, Vandeplassche L, Kerstens R et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation- A 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009 ; 29 : 315-28.
12. Tack J, Quigley E, Camilleri M et al. Efficacy and safety of oral prucalopride in women with chronic constipation in whom laxatives have failed: an integrated analysis. United European Gastroenterol J 2013 ; 1 : 48-59.
13. Tack J, Stanghellini V, Dubois D et al. Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 2014 ; 26 : 21-7.
14. Ke M, Zou D, Yuan Y et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012 ; 24 : 999-e541.
15. Shin A, Camilleri M, Kolar G et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014 ; 39 : 239-53.
16. ICH harmonised tripartite guidelines for good clinical practice 1996. ICH Harmonised Tripartite Guidelines for Good Clinical Practice, 1996 ; http://www.ich.org/fi leadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf Accessed 11 June 2012.
17. World Medical Association. Declaration of Helsinki: ethical principles for medical researchinvolving human subjects. http://www.wma.net/e/policy/b3.htm [Cited 12 August 2009].
18. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997 ; 32 : 920-4.
19. Frank L, Kleinman L, Farup C et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999 ; 34 : 870-7.
20. Dubois D, Gilet H, Viala-Danten M et al. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil 2010 ; 22 : e54-63.
21. Marquis P, De La Loge C, Dubois D et al. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol 2005 ; 40 : 540-51.
22. Camilleri M, Beyens G, Kerstens R et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009 ; 21 : 1256-e117.
23. Mendzelevski B, Ausma J, Chanter DO et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo-and positive-controlled thorough QT study. B r J Clin Pharmacol 2 012; 7 3: 2 03-9.
24. Chapman H, Pasternack M. The action of the novel gastrointestinal prokinetic prucalopride on the HERG K+ channel and the common T897 polymorph. Eur J Pharmacol 2007 ; 554 : 98-105.